A Safety Study of NNZ-2566 in Patients With Fragile X Syndrome

Phase 2

Completed

• Conditions: Fragile X Syndrome
• Interventions: Drug: NNZ-2566; Drug: Placebo

• Registration Number: NCT01894958
• Lead Sponsor: Neuren Pharmaceuticals Limited

Brief Summary

The purpose of this study is to determine whether NNZ-2566 is safe and well tolerated in the treatment of Fragile X Syndrome in adolescent and adult males.

Detailed Description

Fragile X Syndrome is a genetically determined neurological disorder in which affected individuals are intellectually handicapped to varying degrees and display a variety of associated psychiatric symptoms. Clinically, Fragile X Syndrome is characterized by intellectual handicap, hyperactivity and attentional problems, autism spectrum symptoms, emotional lability and epilepsy. The epilepsy seen in Fragile X Syndrome is most commonly present in childhood, but then gradually remits towards adulthood. Physical features such as prominent ears and jaw, and hyper-extensibility of joints are frequently present but are not diagnostic. Intellectual handicap is the most common feature defining the phenotype. Treatment for the disorder is symptomatic - focusing on the management of symptoms - and supportive, requiring a multidisciplinary approach.

This study will investigate the safety and tolerability of treatment with oral administration of NNZ-2566 at 35 mg/kg or 70 mg/kg BID in adolescent or adult males with Fragile X Syndrome. The study also will also investigate measures of efficacy during treatment.

Study Timeline

• Study First Submitted: 2013-07-03
• Study First Submitted QC: 2013-07-03
• Study First Posted: 2013-07-10
• Study Start: 2014-01
• Primary Completion: 2015-09
• Study Completion: 2015-10
• Status Verified: 2018-01
• Disposition First Submitted: 2018-01-31
• Disposition First Submitted QC: 2018-01-31
• Last Update Submitted: 2018-01-31
• Disposition First Posted: 2018-02-05
• Last Update Posted: 2018-02-05

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 72

Inclusion Criteria

1. Fragile X Syndrome with a molecular genetic confirmation of the full FMR1 mutation.

   • Results from previously completed testing are acceptable with written documentation of the genetic results.

   • Results from PCR or Southern blot tests are acceptable

   • Results from cytogenetic testing are not acceptable but subject may be eligible if molecular genetic testing is redone.

   • A full mutation with mosaicism is allowed if:

     • Subject manifests full phenotypic profile of Fragile X syndrome
     • CGG Repeats >200 are detected
     • Southern blot prevails over PCR, if Southern blot shows >200 repeats and PCR results show <200 repeats.

   • The following results would not meet criteria:

     • Deletions
     • Point mutations
     • Mosaicism without detection of >200 CGG repeats or absence of full phenotypic profile in an individual with mosaicism

2. Males, aged 12-45 years

3. Subjects with a Clinical Global Impression - Severity (CGI-S) score of 4 or greater at Screening

4. Subjects with a total score of 30 or greater on the Aberrant Behavior Checklist (ABC) at Screening.

5. Current treatment with no more than 3 psychotropic medications. This includes medications used to treat problems with sleep onset and sleep continuity. Melatonin for difficulties with sleep onset is permissible and is excepted from the count of psychotropic medications. Similarly, anti-epileptic medications are permitted and are not denoted as "psychotropic medications" if they are used for treatment of seizures. Use of anti-epileptics for other indications such as the treatment of mood disorders counts towards the limit of permitted medications. Concurrent use of omega-3 fatty acids is also permissible and does not count towards the allowed number of concomitant psychotropic medications. A complete list of permitted concomitant psychotropic medications can be found in Appendix A.

6. Concomitant medications for chronic medical conditions are permissible. Examples of chronic medical conditions include gastroesophageal reflux disease (GERD) and asthma. Every effort should be made to keep the doses and dosing regimens of these medications stable in the 4 weeks preceding Screening and during the period between Screening and the commencement of study medication.

   1. Permitted psychotropic concomitant medications (except for anti-epileptic medications-see below) must be stable, in terms of dose and dosing regimen, for at least 4 weeks prior to Screening and must remain stable during the period between Screening and the commencement of study medication.
   2. Anti-epileptic medications must be at a stable dose and dosing regimen for 12 weeks prior to Screening and must remain stable during the period between Screening and the commencement of study medication

7. Behavioral treatments excluding psychotherapy (see exclusion criteria) must be stable for 4 weeks prior to Screening and must remain stable during the period between Screening and the commencement of study medication

   a. For each enrollee, every effort should be made to maintain stable regimens of allowed concomitant medications and allowed behavioral therapies from the time of commencement of single-blind study medication until the last study assessment.

8. Sufficient expressive language capabilities to complete the Expressive Language Sampling Task.

9. Individuals with a history of seizures should have a stable pattern of seizure activity in the 3 months preceding Screening.

Read More

Exclusion Criteria

1. Treatment within the two weeks prior to Screening with monoamine (MAO) inhibitors, lithium, minocycline, acamprosate, racemic baclofen, investigational metabotropic glutamate receptor subtype 5 (mGluR5) medications, d-cycloserine, oxytocin, carbetocin, tricyclic antidepressants and bupropion.

2. Patients planning to commence psychotherapy, including cognitive behavior therapy (CBT), during the period of the study or those who had begun psychotherapy, including CBT, within 6 weeks prior to Screening.

3. History of, or current, cardiovascular, renal, hepatic, respiratory and/or gastrointestinal disease, which may interfere with the absorption, distribution, metabolism or excretion of the study medication, or which may interfere with the interpretation of the safety/tolerability or efficacy of the study medication.

4. History of, or current cerebrovascular disease or clinically significant brain trauma.

5. History of, or current clinically significant endocrine disorder, e.g. hypo or hyperthyroidism, or diabetes.

6. History of, or current malignancy.

7. Current major depressive disorder (patients have to be free of the most recent episode for 3 months prior to enrollment).

8. History of a DSM-5-defined substance use disorder in the 3 months prior to Screening.

9. Clinically significant abnormalities in safety laboratory tests, vital signs or ECG, as measured at Screening.

10. QT/QTcF Exclusions (any of the following):

    • QTcF > 450 msec. Three ECGs should be obtained at the time of Screening, 5 minutes apart from each other, and the results should be averaged.
    • History of risk factors for torsade de pointes (e.g. heart failure, clinically significant hypokalemia or hypomagnesemia, or a family of long QT syndrome).
    • A serum potassium at screening <3.0 mmol/L.
    • QT/QTcF prolongation previously or currently controlled with medication, in which normal QT/QTcF intervals could or can only be achieved with medication
    • Current treatment with other medications that have demonstrated QT/QTc prolongation and have this risk described in the Warnings and Precautions section of their Prescribing Information

11. Patients with significant hearing and/or visual impairments that may affect their ability to complete the test procedures.

12. Current treatment with insulin

13. Hgb A1C values outside of the normal reference range at Screening

14. Current or past treatment with insulin like growth factor IGF-1

15. Current or past treatment with growth hormone

16. Enrollment in another clinical trial within the 30 days preceding Screening

17. Previously randomized in this clinical trial

18. Allergy to strawberry

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
NNZ-2566	NNZ-2566	Glycyl-L-2-Methylpropyl-L-Glutamic Acid
Placebo (strawberry flavored solution)	Placebo	Strawberry flavored solution and Water

Primary Outcome Measures

Name	Time	Method
Adverse events	Through to Day 56	Incidence of adverse events (AE), including Serious adverse events (SAE), will be evaluated between the two NNZ-2566 doses and placebo. Incidence of AEs from randomized dosing through to Day 56 post randomization. Incidence of SAEs from randomization through to Day 56 post randomization.

Secondary Outcome Measures

Name	Time	Method
Behavior	Baseline through to Day 56	Symptom severity according to the Fragile X Symptom Rating Scale, Clinician Domain Specific Top Three Concerns-VAS, Aberrant Behavior Checklist (ABC), Vineland Adaptive Behavior Scale (VABS), Child and Adolescent Symptom Inventory-Anxiety Scale (CASI-16), Children's Yale-Brown Obsessive Compulsive Scale (CYBOCS-PDD), Expressive Language Sampling and Clinical Global Impression of Severity (CGI-S).
Physiological changes	Baseline through to Day 56	Serum levels and changes of standard hematology, and chemistry parameters (including thyroid function) will be calculated from Baseline through to Day 56. Fundoscopy and tonsil size will be documented at Baseline, and Days 14, 28, 42 and 56. Flow cytometry will be used to assess the phosphorylation status of the enzymes Akt and extracellular signal-regulated kinase (ERK) in peripheral lymphocytes, on blood samples obtained on Days 14, 28, 42 and 56. Electrocardiogram (ECG) will be assessed at Screening, Days 14, 21, 28, 35, 42 and 56.
Global and Functional outcome Measures	Baseline through to Day 56	Global outcome as measured by the change in scores in the Clinical Global Impression - Severity and Improvement scales (CGI-S and -I) and the KiTap measure of cognition from baseline, during treatment, and post treatment.; Global and Functional outcome as measured by changes in scores in the Fragile X Symptom Rating Scale, Clinician Domain Specific Top Three Concerns-VAS, Caregiver Top Three Concerns (related to the subject's Fragile X syndrome) as assessed via a Visual Analogue Scale (VAS), CASI-20, CYBOCS-PDD, Aberrant Behavior Checklist (ABC), Vineland Adaptive Behavior Scales (VABS) and Expressive Language Sampling will be assessed during treatment.

Trial Locations

Locations (17)

Emory University; 🇺🇸 Atlanta, Georgia, United States

University of Nebraska; 🇺🇸 Omaha, Nebraska, United States

UC Davis MIND Institute; 🇺🇸 Sacramento, California, United States

Mount Sinai School of Medicine; 🇺🇸 New York, New York, United States

Rush University Medical Center; 🇺🇸 Chicago, Illinois, United States

Kennedy Krieger Institute; 🇺🇸 Baltimore, Maryland, United States

Autism & Developmental Medicine Institute Geisinger Health System; 🇺🇸 Lewisburg, Pennsylvania, United States

University of Michigan; 🇺🇸 Ann Arbor, Michigan, United States

Suburban Research Associates; 🇺🇸 Media, Pennsylvania, United States

Greenwood Genetic Center; 🇺🇸 Greenwood, South Carolina, United States

Vanderbilt University Medical Center; 🇺🇸 Nashville, Tennessee, United States

Children's Hospital Colorado; 🇺🇸 Denver, Colorado, United States

Cincinnati Children's Hospital Medical Center; 🇺🇸 Cincinnati, Ohio, United States

University of Massachusetts Medical School; 🇺🇸 Worcester, Massachusetts, United States

Children's National Hospital; 🇺🇸 Washington, District of Columbia, United States

Texas Children's Hospital; 🇺🇸 Houston, Texas, United States

Seattle Children's Hospital; 🇺🇸 Seattle, Washington, United States